Skip to main content
logo
Merck KGaA (BIT:1MRK)
Italy flag Italy · Delayed Price · Currency is EUR
112.50
-1.05 (-0.92%)
At close: Jul 25, 2025, 5:30 PM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Other
200.00K
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-133.33%
Log In
Log In
Log In
Log In
Upgrade
Life Science
-
Log In
Log In
Log In
Log In
Upgrade
Life Science Growth
-
Log In
Log In
Log In
Log In
Upgrade
Oncology
2.01B
Log In
Log In
Log In
Log In
Upgrade
Oncology Growth
6.05%
Log In
Log In
Log In
Log In
Upgrade
Neurology & Immunology
1.69B
Log In
Log In
Log In
Log In
Upgrade
Neurology & Immunology Growth
-1.00%
Log In
Log In
Log In
Log In
Upgrade
Fertility
1.53B
Log In
Log In
Log In
Log In
Upgrade
Fertility Growth
-2.33%
Log In
Log In
Log In
Log In
Upgrade
Display Solutions
748.30M
Log In
Log In
Log In
Log In
Upgrade
Display Solutions Growth
-1.34%
Log In
Log In
Log In
Log In
Upgrade
Surface Solutions
406.50M
Log In
Log In
Log In
Log In
Upgrade
Surface Solutions Growth
-2.83%
Log In
Log In
Log In
Log In
Upgrade
Semiconductor Solutions
2.63B
Log In
Log In
Log In
Log In
Upgrade
Semiconductor Solutions Growth
5.59%
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular, Metabolism and Endocrinology
2.95B
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular, Metabolism and Endocrinology Growth
7.81%
Log In
Log In
Log In
Log In
Upgrade
Other Healthcare
280.50M
Log In
Log In
Log In
Log In
Upgrade
Other Healthcare Growth
18.35%
Log In
Log In
Log In
Log In
Upgrade
Process Solutions
3.52B
Log In
Log In
Log In
Log In
Upgrade
Process Solutions Growth
1.31%
Log In
Log In
Log In
Log In
Upgrade
Life Science Services
721.80M
Log In
Log In
Log In
Log In
Upgrade
Life Science Services Growth
-5.93%
Log In
Log In
Log In
Log In
Upgrade
Science & Lab Solutions
4.67B
Log In
Log In
Log In
Log In
Upgrade
Science & Lab Solutions Growth
1.11%
Log In
Log In
Log In
Log In
Upgrade
Other
200.00K
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-133.33%
Log In
Log In
Log In
Log In
Upgrade

EBITDA by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Life Science EBITDA
2.59B
Log In
Log In
Log In
Log In
Upgrade
Life Science EBITDA Growth
2.77%
Log In
Log In
Log In
Log In
Upgrade
Healthcare EBITDA
2.99B
Log In
Log In
Log In
Log In
Upgrade
Healthcare EBITDA Growth
15.82%
Log In
Log In
Log In
Log In
Upgrade
Electronics EBITDA
969.60M
Log In
Log In
Log In
Log In
Upgrade
Electronics EBITDA Growth
7.14%
Log In
Log In
Log In
Log In
Upgrade
Corporate/Others EBITDA
-481.80M
Log In
Log In
Log In
Log In
Upgrade
Corporate/Others EBITDA Growth
41.65%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Europe
6.17B
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
4.84%
Log In
Log In
Log In
Log In
Upgrade
North America
5.71B
Log In
Log In
Log In
Log In
Upgrade
North America Growth
-2.24%
Log In
Log In
Log In
Log In
Upgrade
Asia Pacific
7.02B
Log In
Log In
Log In
Log In
Upgrade
Asia Pacific Growth
2.55%
Log In
Log In
Log In
Log In
Upgrade
Latin America
1.48B
Log In
Log In
Log In
Log In
Upgrade
Latin America Growth
7.73%
Log In
Log In
Log In
Log In
Upgrade
Middle East & Africa
781.20M
Log In
Log In
Log In
Log In
Upgrade
Middle East & Africa Growth
7.44%
Log In
Log In
Log In
Log In
Upgrade